IgA Nephropathy

  • Aris OatesEmail author


IgAN, once thought to be a benign entity in children and adults, is a common cause of glomerulonephritis worldwide and a major cause of ESRD. In this chapter we review the worldwide epidemiology of the disease in adolescents and children to explore the pathologic and histologic defining features. Consensus diagnosis and treatment options are discussed. Established as a slowly progressive disease with variable course, close follow-up, and optimized supportive care is recommended in patients without severe disease to help improve renal survival. Investigations into the optimal subset of patients to benefit from immunosuppressive therapy and new treatment targets are ongoing.


Immunoglobulin A Glomerulonephritis Immune complex nephropathy Mesangial deposits Macroscopic hematuria End-stage renal disease 



End-stage renal disease


Genome-wide association studies


Immunoglobulin A nephropathy


Kidney disease improving global outcomes



The authors wish to thank Dr. Zoltan Laszik for the pathology images in Figs. 7.1, 7.2, and 7.3.


  1. 1.
    Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1969;1(4):939–44.PubMedGoogle Scholar
  2. 2.
    Yoshikawa N, Tanaka R, Iijima K. Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol. 2001;16(5):446–57.PubMedCrossRefGoogle Scholar
  3. 3.
    D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709–27.PubMedGoogle Scholar
  4. 4.
    Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23(8):2537–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Ronkainen J, Ala-Houhala M, Autio-Harmainen H, Jahnukainen T, Koskimies O, Merenmies J, et al. Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol. 2006;21(9):1266–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol. 2015;30(12):2121–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Moreno JA, Martín-Cleary C, Gutiérrez E, Rubio-Navarro A, Ortiz A, Praga M, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transplant. 2012;27(1):28–34.PubMedCrossRefGoogle Scholar
  8. 8.
    Delos Santos NM, Wyatt RJ. Pediatric IgA nephropathies: clinical aspects and therapeutic approaches. Semin Nephrol. 2004;24(3):269–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60(1):60–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000;57(5):1818–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89(2):209–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S 3rd, Holland NH, et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr. 1995;127(6):913–9.PubMedCrossRefGoogle Scholar
  13. 13.
    McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Hogg RJ. Idiopathic immunoglobulin A nephropathy in children and adolescents. Pediatr Nephrol. 2010;25(5):823–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Shibano T, Takagi N, Maekawa K, Mae H, Hattori M, Takeshima Y, et al. Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol. 2016;20(1):111–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Utsunomiya Y, Koda T, Kado T, Okada S, Hayashi A, Kanzaki S, et al. Incidence of pediatric IgA nephropathy. Pediatr Nephrol. 2003;18(6):511–5.PubMedGoogle Scholar
  19. 19.
    Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant. 1998;13(2):293–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Orta-Sibu N, Lopez M, Moriyon JC, Chavez JB. Renal diseases in children in Venezuela, South America. Pediatr Nephrol. 2002;17(7):566–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Ikezumi Y, Suzuki T, Imai N, Ueno M, Narita I, Kawachi H, et al. Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant. 2006;21(12):3466–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Wyatt RJ, Julian BA, Baehler RW, Stafford CC, McMorrow RG, Ferguson T, et al. Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol. 1998;9(5):853–8.PubMedGoogle Scholar
  23. 23.
    Sehic AM, Gaber LW, Roy S 3rd, Miller PM, Kritchevsky SB, Wyatt RJ. Increased recognition of IgA nephropathy in African-American children. Pediatr Nephrol. 1997;11(4):435–7.PubMedCrossRefGoogle Scholar
  24. 24.
    McQuarrie EP, Mackinnon B, McNeice V, Fox JG, Geddes CC. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation. Kidney Int. 2014;85(1):198–203.PubMedCrossRefGoogle Scholar
  25. 25.
    Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis. 1985;6(2):100–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Hoshino Y, Kaga T, Abe Y, Endo M, Wakai S, Tsuchiya K, et al. Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria. Clin Exp Nephrol. 2015;19(5):918–24.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Clarkson AR, Woodroffe AJ, Aarons I, Hiki Y, Hale G. IgA nephropathy. Annu Rev Med. 1987;38:157–68.PubMedCrossRefGoogle Scholar
  28. 28.
    Yoshikawa N, Yoshiara S, Yoshiya K, Matsuo T, Okada S. Lysis of the glomerular basement membrane in children with IgA nephropathy and Henoch-Shönlein nephritis. J Pathol. 1986;150(2):119–26.PubMedCrossRefGoogle Scholar
  29. 29.
    Lai KN. Pathogenic IgA in IgA nephropathy: still the blind men and the elephant? Kidney Int. 2006;69(7):1102–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004;24(3):197–217.PubMedCrossRefGoogle Scholar
  31. 31.
    Hiki Y, Saitoh M, Kobayashi Y. Serum IgA class anti-IgA antibody in IgA nephropathy. Nephron. 1991;59(4):552–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Iijima K, Yoshikawa N, Shiozawa S, Matsuyama S, Kobayashi K, Yoshiya K, et al. Immune abnormalities and clinical course in childhood IgA nephropathy. Nephron. 1990;56(3):255–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Kameda A, Yoshikawa N, Shiozawa S, Doi K, Nakamura H. Lymphocyte subpopulations and function in childhood IgA nephropathy. Nephron. 1991;59(4):546–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Lai KN, Leung JCK. Pathogenic role of the IgA molecule in IgA nephropathy. Nephrology. 2002;7:S86–91.CrossRefGoogle Scholar
  35. 35.
    Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int. 2002;62(2):465–75.PubMedCrossRefGoogle Scholar
  36. 36.
    Sano T, Hiki Y, Kokubo T, Iwase H, Shigematsu H, Kobayashi Y. Enzymatically deglycosylated human IgA1 molecules accumulate and induce inflammatory cell reaction in rat glomeruli. Nephrol Dial Transplant. 2002;17(1):50–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668–77.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20(2):342–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee MJ, Kim SJ, Oh HJ, Ko KI, Koo HM, Kim CH, et al. Clinical implication of crescentic lesions in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29(2):356–64.PubMedCrossRefGoogle Scholar
  40. 40.
    Abuelo JG, Esparza AR, Matarese RA, Endreny RG, Carvalho JS, Allegra SR. Crescentic IgA nephropathy. Medicine. 1984;63(6):396–406.PubMedCrossRefGoogle Scholar
  41. 41.
    Utsunomiya Y, Kawamura T, Abe A, Imai H, Hirano K, Maruyama N, et al. Significance of mesangial expression of alpha-smooth muscle actin in the progression of IgA nephropathy. Am J Kidney Dis. 1999;34(5):902–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77(10):921–7.CrossRefGoogle Scholar
  43. 43.
    Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.CrossRefGoogle Scholar
  44. 44.
    Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–21.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–36.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Wyatt RJ, Emancipator SN, Kon V, Waldo FB, Donadio J, Grande JP, et al. IgA nephropathy databank: development of a system for management of renal biopsy acquired data. Am J Kidney Dis. 1997;29(6):817–28.PubMedCrossRefGoogle Scholar
  47. 47.
    Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts ISD, Feehally J, et al. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int [Internet]. 2015; Scholar
  49. 49.
    Yoon C-Y, Chang TI, Kang EW, Lim BJ, Kie JH, Kee YK, et al. Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. Ann Med. 2017;49(3):217–29.PubMedCrossRefGoogle Scholar
  50. 50.
    Le W, Zeng C-H, Liu Z, Liu D, Yang Q, Lin R-X, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol. 2012;13:158.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Shima Y, Nakanishi K, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy. Pediatr Nephrol. 2015;30(2):293–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, et al. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol. 2017;32(1):139–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Lau KK, Butani L. Treatment of pediatric IgA nephropathy. Hong Kong J Nephrol. 2007;9(2):70–6.CrossRefGoogle Scholar
  54. 54.
    Chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl. 2012;2(2):209–17.Google Scholar
  55. 55.
    Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24(3):218–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 1998;9(7):1213–24.PubMedGoogle Scholar
  57. 57.
    Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.PubMedCrossRefGoogle Scholar
  58. 58.
    Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper A-L, Maschio G, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67(1):265–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM. 2005;98(3):199–203.PubMedCrossRefGoogle Scholar
  60. 60.
    Doggrell SA. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Expert Opin Pharmacother. 2003;4(7):1185–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361(9352):117–24.PubMedCrossRefGoogle Scholar
  62. 62.
    Chow K-M, Szeto C-C, Kwan BC-H, Leung C-B, Chung K-Y, Li PK-T. Dual therapy with ACE inhibitors and angiotensin II receptor blockers in proteinuric IgA nephropathy patients. Hong Kong J Nephrol. 2007;9(2):89–93.CrossRefGoogle Scholar
  63. 63.
    Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64(1):35–40.PubMedCrossRefGoogle Scholar
  64. 64.
    Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903.CrossRefGoogle Scholar
  65. 65.
    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRefGoogle Scholar
  66. 66.
    Fuiano G, Mancuso D, Cianfrone P, Comi N, Mazza G, Marino F, et al. Can young adult patients with proteinuric IgA nephropathy perform physical exercise? Am J Kidney Dis. 2004;44(2):257–63.PubMedCrossRefGoogle Scholar
  67. 67.
    Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol. 2008;23(3):363–71.PubMedCrossRefGoogle Scholar
  68. 68.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.CrossRefGoogle Scholar
  69. 69.
    ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–50.CrossRefGoogle Scholar
  70. 70.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.PubMedCrossRefGoogle Scholar
  71. 71.
    Kawasaki Y, Takano K, Suyama K, Isome M, Suzuki H, Sakuma H, et al. Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy. Pediatr Nephrol. 2006;21(11):1701–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Duan J, Liu D, Duan G, Liu Z. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis. Int Urol Nephrol. 2017;49(1):103–12.PubMedCrossRefGoogle Scholar
  73. 73.
    Liu L-L, Wang L-N, Jiang Y, Yao L, Dong L-P, Li Z-L, et al. Tonsillectomy for IgA nephropathy: a meta-analysis. Am J Kidney Dis. 2015;65(1):80–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012;27(3):1090–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994;331(18):1194–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011;16(3):CD003962.Google Scholar
  77. 77.
    Chou H-H, Chiou Y-Y, Hung P-H, Chiang P-C, Wang S-T. Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials. Nephron Clin Pract. 2012;121(1–2):c30–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2006;1(6):1167–72.PubMedCrossRefGoogle Scholar
  79. 79.
    Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015;(8):CD003965.Google Scholar
  81. 81.
    Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23(6):1108–16.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–63.PubMedCrossRefGoogle Scholar
  83. 83.
    Clive DM, Galvanek EG, Silva FG. Mesangial immunoglobulin A deposits in minimal change nephrotic syndrome: a report of an older patient and review of the literature. Am J Nephrol. 1990;10(1):31–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747–57.PubMedCrossRefGoogle Scholar
  85. 85.
    Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003;18(7):1321–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13(1):142–8.PubMedGoogle Scholar
  87. 87.
    Xie X, Lv J, Shi S, Zhu L, Liu L, Chen M, et al. Plasma exchange as an adjunctive therapy for crescentic IgA nephropathy. Am J Nephrol. 2016;44(2):141–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306–13.PubMedCrossRefGoogle Scholar
  89. 89.
    Peng W, Tang Y, Jiang Z, Li Z, Mi X, Qin W. The effect of calcineurin inhibitors in the treatment of IgA nephropathy: a systematic review and meta-analysis (PRISMA). Medicine. 2016;95(35):e4731.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Ring T, Pedersen BB, Salkus G, Goodship THJ. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J. 2015;8(5):489–91.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol. 1993;7(5):529–32.PubMedCrossRefGoogle Scholar
  92. 92.
    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999;10(1):101–9.PubMedGoogle Scholar
  93. 93.
    Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301–7.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1(3):511–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Hsu SI-H. Racial and genetic factors in IgA nephropathy. Semin Nephrol. 2008;28(1):48–57.PubMedCrossRefGoogle Scholar
  96. 96.
    Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23. Nat Genet. 2000;26(3):354–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21(10):1791–7.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321–7.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Yu X-Q, Li M, Zhang H, Low H-Q, Wei X, Wang J-Q, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. 2011;44(2):178–82.PubMedCrossRefGoogle Scholar
  100. 100.
    Lai KN, Chan LYY, Tang SCW, Tsang AWL, Li FFK, Lam MF, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int. 2004;66(4):1403–16.PubMedCrossRefGoogle Scholar
  101. 101.
    Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int. 2000;57(1):274–81.PubMedCrossRefGoogle Scholar
  102. 102.
    Odum J, Peh CA, Clarkson AR, Bannister KM, Seymour AE, Gillis D, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant. 1994;9(3):309–12.PubMedGoogle Scholar
  103. 103.
    Wang AY, Lai FM, Yu AW, Lam PK, Chow KM, Choi PC, et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis. 2001;38(3):588–96.PubMedCrossRefGoogle Scholar
  104. 104.
    Chandrakantan A, Ratanapanichkich P, Said M, Barker CV, Julian BA. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant. 2005;20(6):1214–21.PubMedCrossRefGoogle Scholar
  105. 105.
    Namba Y, Oka K, Moriyama T, Ichimaru N, Kyo M, Kokado Y, et al. Risk factors for graft loss in patients with recurrent IGA nephropathy after renal transplantation. Transplant Proc. 2004;36(5):1314–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Lionaki S, Panagiotellis K, Melexopoulou C, Boletis JN. The clinical course of IgA nephropathy after kidney transplantation and its management. Transplant Rev [Internet]. 2017; Scholar
  107. 107.
    Ponticelli C, Traversi L, Feliciani A, Cesana BM, Banfi G, Tarantino A. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int. 2001;60(5):1948–54.PubMedCrossRefGoogle Scholar
  108. 108.
    Freese P, Svalander C, Nordén G, Nyberg G. Clinical risk factors for recurrence of IgA nephropathy. Clin Transpl. 1999;13(4):313–7.CrossRefGoogle Scholar
  109. 109.
    Floege J. Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004;24(3):287–91.PubMedCrossRefGoogle Scholar
  110. 110.
    Berthoux F, El Deeb S, Mariat C, Diconne E, Laurent B, Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation. 2008;85(10):1505–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Kessler M, Hiesse C, Hestin D, Mayeux D, Boubenider K, Charpentier B. Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis. 1996;28(1):99–104.PubMedCrossRefGoogle Scholar
  112. 112.
    Han SS, Huh W, Park SK, Ahn C, Han JS, Kim S, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int. 2010;23(2):169–75.PubMedCrossRefGoogle Scholar
  113. 113.
    Hotta K, Fukasawa Y, Akimoto M, Tanabe T, Sasaki H, Fukuzawa N, et al. Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology. 2013;18(12):808–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of CaliforniaSan FranciscoUSA

Personalised recommendations